# A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects

> **NCT03960489** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Healthy Adult Subjects

## Interventions

- **DRUG:** Roxadustat

## Key facts

- **NCT ID:** NCT03960489
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-31
- **Primary completion:** 2019-10-14
- **Final completion:** 2019-10-14
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03960489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03960489, "A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03960489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*